Japan's "Yomiuri Shimbun" disclosed that the Japanese pharmaceutical company Far East was suspected of falsifying data and shipping Zhenglu Pill, a gastrointestinal medicine with insufficient ingredients, and the Toyama County Government urgently stopped production and sales. The company was also revealed to have violated regulations by failing to conduct quality tests when sourcing raw materials and directly using manufacturer data. Although there have been no reports of health damage, pharmaceutical companies in Toyama Prefecture have been involved in manufacturing misconduct on several occasions in recent years. This is the seventh such incident in the past five years. Not long ago, Kobayashi Pharmaceutical also exposed similar problems, resulting in 5 deaths and 257 hospitalizations. Drug safety issues in Japan have once again aroused public concern. #胃肠药正露丸数据造假30年#
